Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma
Bilgin, Gokce Belge , Nikanpour, Yalda , Kipp, Benjamin R. , Zahrieh, David M. , Block, Matthew S. , Stoff, Ronen , Geiersbach, Katherine B. , Johnson, Geoffrey B. , Markovic, Svetomir N.

Mayo Clinic

International Journal of Cancer | April 21, 2026 | Volume: 159 | Issue: 4 | Pages: 1068-1078

10.1002/ijc.70514 | PMID 42011804 Get It

ABSTRACT Circulating tumor DNA (ctDNA) as a liquid biopsy is an emerging tool used for diagnosis and disease monitoring, yet not all tumors shed DNA equally, thus currently limiting the clinical applicability of this tool. Our institution has developed and validated a droplet digital Polymerase Chain Reaction (ddPCR) ctDNA test for BRAF V600 mutation. We collected data on all BRAF mutated melanoma patients tested with the ddPCR BRAF assay at our institution over the years 2018–2024 and correlated the test results with clinical and radiological baseline parameters, with a focus on Positron Emission Tomography‐Computed Tomography (PET‐CT) data, incorporating both location of lesions and volume of disease. Linear and logistic regression modelling was used to assess possible associations between the baseline parameters and the ctDNA results. We identified 71 BRAF mutated melanoma patients, of which 65 had active disease on imaging studies and 43 had PET‐CT data available for analysis. Multivariate modelling has shown that patients were more likely to have a positive ctDNA result if they had elevated serum lactate dehydrogenase (LDH) (OR = 9.9), had a higher number of lesions on imaging studies (> 10 lesions: OR = 11.3), and if they were younger than 65 (OR = 11.8), with an AUC of 0.84. The PET‐CT calculated total metabolic tumor volume correlated with the quantitative ctDNA result with a Pearson r factor of 0.49. In conclusion, ctDNA ddPCR BRAF testing is easily obtained and might be especially beneficial for patients diagnosed with a clinically aggressive disease, based on elevated LDH, higher PET‐CT metabolic tumor volume, and younger age.
COASY-Associated Disorders as a Differential Diagnosis in Cases with Newborn Screening Results Suggestive of CPT-I
Stander, Zinandré, White, Amy , Lynch, Matthew, Rosati, Justin , Bailey, Diana, Johnson, Jessica, Lee, Bo Hoon , Fong, ChinTo, Orsini, Joseph, Schultz, Matthew J, Gavrilov, Dimitar , Matern, Dietrich , Hall, Patricia L., Tortorelli, Silvia , Orsini, Joseph J. , White, Amy L , Lee, Bo Hoon , Orsini, Joseph J , Matern, Dietrich , Tortorelli, Silvia , Stander, Zinandré , Lynch, Matthew , Coman, David , Bailey, Diana, Oglesbee, Devin

Mayo Clinic

International Journal of Neonatal Screening | April 17, 2026 | Volume: 12 | Issue: 2 | Pages: 25

10.3390/ijns12020025 | PMID 42029543 Get It

COASY-related disorders (CRDs) are a spectrum of autosomal recessive conditions caused by the dysfunction of CoA synthase, an enzyme responsible for the final steps of CoA synthesis. Clinical manifestations of CRDs are highly variable, ranging from perinatal lethal pontocerebellar hypoplasia to childhood-onset neurodegenerative brain iron accumulation, which is often recognized after clinical regression. Recent reports have described a few individuals with CRD who screened positive for carnitine palmitoyltransferase-I deficiency by newborn screening (NBS). However, heterogeneous clinical presentations, conflicting biochemical/molecular sequencing of CPT1A, and a lack of metabolic characterization have led to lengthy, costly diagnostic journeys. To address some of these aspects, this investigation retrospectively evaluated NBS acylcarnitine patterns in five CRD cases using Collaborative Laboratory Integrated Reports (CLIR). A total of 25 metabolites/ratios were identified to deviate significantly from reference ranges and were primarily composed of elevated free carnitine and reduced long-chain acylcarnitine levels. While low acylcarnitine concentrations are often not reported due to a lack of lower reference cutoffs, ratios involving these metabolites relative to short-chain acylcarnitines could aid in identifying CRD cases via NBS. When comparing this pattern to CPT-Ia cases, we confirmed a nearly identical acylcarnitine pattern between these, and thus support the need to consider CRD in cases with NBS results suggestive of CPT-Ia. This study is the first case series to characterize NBS patterns in patients with CRD and highlights the unique opportunity for early detection, particularly in cases that are neonatally asymptomatic and have unremarkable confirmatory biochemical results.
Operative Strategies and Wound Complications for Morel-Lavallee Injuries Undergoing Excisional Debridement: A Pacific Coast Surgical Association Multicenter Study
Nguyen, Peter , Grigorian, Areg , Costantini, Todd, Santorelli, Jarrett, Husen, Lilian Von, Inaba, Kenji, Schellenberg, Morgan, Stephens, Daniel, Chaar, Mohamad Abou, Mahmoud, Khalid, Schreiber, Martin, Minoza, Karen, Underwood, Samantha, Biffl, Walter, Lü, Ning , Bayat, Dunya, Edwards, Sara, Tillou, Areti, Zheng, Dennis J. , Plevin, Rebecca E. , Stein, Deborah, Smith, Juliana, Sonntag, Cheyenne C., Callcut, Rachael A. , Furlong, Harly, Graeff, Leonardo Weber, Trevizo, Eric, Cochran-Yu, Meghan, Duncan, Thomas, Diaz, Graal , Neville, Angela , Balan, Naveen , Siletz, Anaar, Ley, Eric, Park, Greigory, Alexander, Juliet, Johnson, Arianne, Cotton-Betteridge, Aaron , Smith, Maren, Alvarez, Claudia, Scolaro, John, Aryan, Negaar , Nahmias, Jeffry, Nguyen, Peter D , Abou Chaar, Mohamad , Lu, Ning , Coimbra, Raul , Balan, Naveen , Alvarez, Claudia , Aryan, Negaar , Costantini, Todd W. , Dilday, Joshua C. , Inaba, Kenji , Schellenberg, Morgan A. , Stephens, Daniel, Chaar, Mohamad K. Abou , Minoza, Karen , Biffl, Walter L. , Tillou, Areti , Kim, Hannah , Graeff, Leonardo W., Duncan, Thomas K. , Kim, Dennis S. , Siletz, Anaar E., Ley, Eric J. , Scolaro, John A. , Nahmias, Jeffry T.

Mayo Clinic

The American Surgeon™ | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/00031348261443695 | PMID 41990323 Get It

Morel-Lavallee lesions (MLLs) are traumatic closed degloving injuries with operative intervention (OI), especially excisional debridement, remaining the mainstay of treatment. However, high-quality evidence describing operative techniques and outcomes remains limited. This study aimed to characterize current OI practices and associated outcomes, especially among patients undergoing excisional debridement, hypothesizing an increased risk of wound complications with this approach for MLLs. Methods This prospective (2021-2024), multicenter, observational study was conducted across 15 trauma centers and included patients diagnosed with MLL who underwent OI. The association between operative technique (eg, excisional debridement) and the primary outcome of wound complications was evaluated. Wound complications were defined as cellulitis, deep wound infection, skin necrosis, necrotizing soft tissue infection (NSTI), and/or organized hematoma. Results Of 88 MLL patients undergoing OI, 36 (40.9%) had excisional debridement, with 4 (11.1%) limited excision to skin, 20 (55.6%) extended to subcutaneous tissue, and 12 (33.3%) down to muscle. Excisional debridement had higher rates of skin necrosis (22.2% vs. 1.9%, P = .002). Although overall rates of wound complications were statistically similar between cohorts (33.3% vs. 17.3%, P = .098), univariate analysis demonstrated excisional debridement had increased risk of wound complications (OR 2.52, CI 1.07-5.97, P = .035). Conclusion This prospective multicenter study over three years demonstrated that a fifth of MLLs undergoing excisional debridement developed postoperative skin necrosis. Excisional debridement also had a more than two-fold increased risk of wound complications compared to other OIs. These findings underscore the importance of investigating alternative operative techniques, such as incision and drainage or minimally invasive debridement methods.
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes
Patel, Vrutti , Sujanyal, Saurabh Ashok , Raavi, Lekhya , Blumenfeld, Sophia G. , Saleem, Faiz , Bateh, Said , Hanson, Abby , Jena, Anek , Isha, Shahin , Pietrzak, Katheleen A. Rottman, Ojard, Michelle, Shah, Sadia Z. , Sanghavi, Devang , Anna, Shapiro, Sujanyal, Saurabh , Rottman Pietrzak, Katheleen A, Ojard, Michelle M , Huespe, Ivan Alfredo , Moreno Franco, Pablo , Edwards, Michael A. , Chauhan, Mohit , Sanghavi, Devang K , Shahin, Isha , Kunze, Katie L. , Johnson, Patrick W. , Pietrzak, Katheleen A., Huespe, Iván , Franco, Pablo Moreno , Chauhan, Mohit

Mayo Clinic

Journal of Intensive Care Medicine | April 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261438474 | PMID 41989186 Get It

Background Ketamine has demonstrated efficacy in treatment-resistant depression, primarily in psychiatric or outpatient populations. Its use in ICU patients remains underexplored, with limited data beyond case reports and small series. This study evaluated the association between subanesthetic ketamine infusions and improvement in depressive symptoms and hemodynamic changes in ICU patients. Methods We conducted a retrospective study of adults admitted to the ICU who received IV ketamine (0.3-0.75 mg/kg over 40 min on three consecutive days) for depressive symptoms. Changes in depressive symptoms were assessed using routine clinical documentation by physicians, nurses, and occupational and physical therapists. Hemodynamic parameters (blood pressure and heart rate) were recorded before and up to 120 min after infusion. The primary outcome was to evaluate depressive symptoms while the secondary outcome was to assess hemodynamic changes post transfusion. Results Thirty-four patients met criteria, including 18 solid organ transplant recipients. Median age was 59 years; 61.8% were male. Ketamine was associated with improvement in apparent sadness (90.0% vs 52.2%, P < .05) and reported sadness (95.0% vs 59.1%, P < .05). In transplant recipients, improvement in apparent sadness remained significant (80.0% vs 41.7%, P < .05). Hemodynamic parameters remained stable; heart rate increased transiently at 15-30 min post-infusion, returning to baseline by 60-90 min. Adverse effects observed were anxiety (12.5%), restlessness and/or agitation (10.4%), and dissociation (8.16%). Conclusion Subanesthetic ketamine improved specific depressive symptoms in critically ill ICU patients without significant hemodynamic instability. These findings support its potential as a rapid-acting antidepressant in the ICU, warranting further prospective trials.
National trends in prescription drug expenditures and projections for 2026
Tichy, Eric M. , Rim, Matthew H, Tadrous, Mina, Schumock, Glen T., Cuéllar, Sandra , Johnson, Thomas J., Newell, Mary Kate, Hoffman, James M. , Tadrous, Mina

Mayo Clinic

American Journal of Health-System Pharmacy | April 15, 2026 | Volume: 83 | Issue: 14 | Pages: 728-744

10.1093/ajhp/zxag115 | PMID 42059345 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2026 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2026 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, endocrine drugs, generics, specialty drugs, and vaccines. For nonfederal hospitals, clinics, and overall (all sectors), estimates for growth of pharmaceutical expenditures in 2026 were made based on a combination of quantitative analyses and expert opinion. Results In 2025, overall pharmaceutical expenditures in the US grew 12.7% compared to 2024, for a total of $915.2 billion. Utilization (a 9.3% increase) drove this increase, while growth due to new drugs (0.9%) and price increases (1.2%) had a modest impact. Tirzepatide was the new top drug in 2025, followed by semaglutide and apixiban. Drug expenditures were $42.9 billion (a 9.6% increase) and $190.5 billion (a 19.0% increase) in nonfederal hospitals and in clinics, respectively. In clinics, volume drove drug expense growth, contributing with a 13.6% increase, while price and new drugs each contributed with a 2.7% increase. In nonfederal hospitals, expenditure growth was driven by increases in volume (4.6%), new products (3.7%), and prices (1.5%). Several new drugs that will influence spending are expected to be approved in 2026. Specialty, endocrine, and cancer drugs will continue to drive expenditures. Conclusion For 2026, we expect overall prescription drug spending to rise by 10.0% to 12.0%, whereas in clinics and hospitals we anticipate increases of 14.0%-16.0% and 4.0%-6.0%, respectively, compared to 2025. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial
Wen, Patrick Y. , Berry, Donald A. , Buxton, Meredith , Colman, Howard , Groot, John de , Lim, Michael, Mellinghoff, Ingo K. , Perry, James, Weller, M, Blondin, Nicholas A., Butt, Omar H. , Damek, Denise M., Fuente, Macarena I. de la , Drappatz, Jan, Dunbar, Erin, Giglio, Pierre , Hyddmark, Emma Viktoria, Iwamoto, Fabio, Jaeckle, Kurt A. , Kim, Lyndon, Kling, Heather M., Lee, Eudocia Q., Mantica, Megan , Mikkelsen, Tom, Newton, Herbert B. , Walbert, Tobias , Weathers, Shiao‐Pei , Lassman, Andrew B. , Group, for the GBM AGILE Regorafenib Study, Alexander, Brian, Anker, Lars , Berry, Nicholas , Cloughesy, Tim, Connelly, Jennifer , Detry, Michelle A. , Fitzgerald, Mark, Gordon, Gary, Graves, Todd, Hu, Jethro , Hyddmark, Emma Maria Viktoria, Johnson, Adam, Kalabic, Marija, Lesser, Glenn J., Marion, Joe , Owen, Scott, Perry, James R, Peters, Katherine B., Powell, Ashley, Saunders, Christina T., Tanner, Kirk, Untch, Sarah, Wilcox, Emma, Yung, W. K. Alfred, Lim, Michael , Buxton, Meredith , de Groot, John , Mellinghoff, Ingo K , Weller, Michael , De La Fuente, Macarena , Lee, Eudocia Q , Mantica, Megan , Nabors, Louis Burt , Newton, Herbert B , Olson, Jeffrey J. , Schiff, David , Walbert, Tobias , Weathers, Shiao-Pei , Cloughesy, Timothy F , Lassman, Andrew B , Berry, Donald , Colman, Howard , Blondin, Nicolas, Drappatz, Jan , Iwamoto, Fabio M., Lee, Eudocia Q. , Mikkelsen, Tom , Nabors, Burt , Newton, Herbert B. , Cloughesy, Timothy F. , Anderson, Mark D., Cavenee, Webster K. , Connelly, Jennifer , Ellingson, Benjamin M. , Galanis, Evanthia , Gordon, Gary, Graber, Jerome J. , Khasraw, Mustafa , Lesser, Glenn J. , McGlothlin, Anna , Peters, Katherine B. , Saunders, Christina T. , Sulman, Erik P. , Tanner, Kirk, Yung, W.K. Alfred

Mayo Clinic

Journal of Clinical Oncology | April 14, 2026 | Volume: 44 | Issue: 18 | Pages: 1676-1686

10.1200/jco-25-01137 | PMID 41980234 Get It

PURPOSE GBM AGILE (ClinicalTrials.gov identifier: NCT03970447 ) is a phase II/III Bayesian adaptive platform registration trial testing multiple arms against a common control; the primary end point is overall survival (OS). Regorafenib, a multikinase inhibitor, showed OS benefit in recurrent (RD) glioblastoma in the phase II REGOMA trial and entered GBM AGILE as the first investigational arm. METHODS Patient subtypes included in the regorafenib arm of GBM AGILE were newly diagnosed unmethylated (NDU) and RD glioblastoma. Prospective defined sets of subtypes, or arm signatures, were NDU, RD, and all (NDU + RD). As the first investigational arm in GBM AGILE, regorafenib was equally randomized to the control arm. Treatment in the control arm is temozolomide + radiotherapy (in newly diagnosed) or lomustine (in RD). Efficacy was assessed by OS hazard ratio (HR), arm/control, and demonstrated when the Bayesian probability of benefit (HR <1.00) was ≥98%. Analysis was performed monthly for limited efficacy, which occurs when the Bayesian predictive power is <25% for all signatures, and determines stopping enrollment. Follow-up continued for 12 months after accrual stopped. RESULTS When the predictive power was <25% in all predefined signatures for regorafenib, accrual stopped for limited efficacy. The final analysis did not demonstrate OS improvement in the regorafenib arm in RD nor NDU glioblastoma. Median HRs were 1.05 (NDU), 1.07 (RD), and 1.07 (all) with final probabilities of benefit (HR <1.00) of 0.421 (NDU), 0.312 (RD), and 0.296 (all). Regorafenib was associated with increased toxicity relative to control. CONCLUSION GBM AGILE did not show superiority of regorafenib over control in RD (lomustine) or NDU (temozolomide + radiotherapy) glioblastoma, yet caused increased toxicities. Regorafenib has been removed from National Comprehensive Cancer Network guidelines as a treatment option for RD.
Peripheral vaccination-induced brain-resident memory CD8+ T cells durably protect mice against intracranial malignancy
Mix, Madison R. , Sievers, Cassie M, Kannan, Shravan Kumar , Pewe, Lecia L. , He, Rui , Fain, Cori E. , Heidarian, Mohammad , Arumugam, Sahaana , Beltz, Terry G., Jin, Fang, Johnson, Aaron J., Hassert, Mariah , Huang, Sunny C. , Hancox, Lisa S. , Jin, Fang, Johnson, Aaron J. , Carter, Calvin S. , Butler, Noah S. , Salem, Aliasger K. , Badovinac, Vladimir P , Harty, John T.

Mayo Clinic

Journal of Clinical Investigation | April 14, 2026 | Volume: 136 | Issue: 8 | Pages: No page available

10.1172/jci197812 | PMID 41983390 Get It

Primary and metastatic brain tumors exhibit resistance to immunotherapies that demonstrate efficacy in peripheral cancer settings. While many immunotherapies aim to enhance CD8 + T cell infiltration and functionality in established tumors, identification of neoantigens support emerging immunopreventative tactics against brain cancer. Functionally potent tissue-resident memory CD8 + T cells (T RM ) can be generated in the brain following peripheral infection or vaccination. However, the ability of brain T RM to prevent intracranial malignancy remains unknown. Here, mice were seeded with tumor-specific or bystander brain T RM via peripheral infection prior to depletion of circulating memory T cells (T CIRCM ) and subsequent brain tumor challenge. Tumor-specific brain T RM durably protected mice against intracranial malignancy even in the absence T CIRCM . These brain T RM persisted in tumor-surviving mice and protected against a second antigen-matched challenge. Importantly, a translationally-relevant mRNA-lipid nanoparticle (LNP) vaccine phenocopied peripheral infection-induced outcomes, generating functional brain T RM that controlled tumor growth. Altogether, this work points to the utility of brain T RM in cancer immunoprevention, supporting the development of antitumor mRNA-LNP vaccines to bolster brain immunity.
Discovery and Preclinical Validation of a Clinically Optimized Mitochondrial Complex I Modulator for Alzheimer’s Disease
Trushin, Sergey , Nguyen, Thi Kim Oanh , Ostroot, Mark , Galkin, Alexander , Nambara, Toshihiko , Lu, Wenyan , Kanekiyo, Takahisa , Johnson, Graham, Trushina, Eugenia , Ostroot, Mark , Nambara, Toshihiko , Trushina, Eugenia

Mayo Clinic

No container title available | April 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.10.717554 | PMID 42039405 Get It

Abstract Alzheimer’s disease (AD) is characterized by diminished capacity to mount adaptive cellular stress responses required to maintain energy homeostasis and proteostasis. An emerging therapeutic strategy is to restore adaptive stress responses by inducing mild energetic stress through inhibition of mitochondrial complex I (mtCI). However, pharmacological inhibition of the respiratory chain has remained challenging, as it can induce bioenergetic failure rather than beneficial signaling. Here, we describe C273, a brain-penetrant small molecule that delivers controlled, weak attenuation of mtCI activity to therapeutically restore endogenous adaptive stress pathways. This work establishes a first-in-class mechanism in which calibrated activation of multifaceted adaptive mechanisms enhances cellular resilience, rather than impairing mitochondrial function. Structure-activity relationship optimization yielded a compound with high potency against Aβ-induced cellular toxicity, strong selectivity for mtCI, and favorable drug-like properties. C273 demonstrated excellent oral bioavailability, metabolic stability in mouse, rat, and human microsomes, minimal CYP liabilities, and a clean ancillary pharmacology profile in the Eurofins CEREP44 panel. In vivo , C273 readily crosses the blood-brain barrier and activates AMP-activated protein kinase (AMPK), initiating a coordinated hormetic response characterized by enhanced antioxidant defenses, suppression of inflammatory signaling, induction of autophagy, and increased mitochondrial biogenesis and turnover. Genetic deletion of AMPKα1/α2 abolished these responses, establishing AMPK as a critical mediator of C273 activity. Pharmacological competition experiments further confirmed the target, as pretreatment with non-toxic concentrations of rotenone blocked C273 interaction with the quinone-binding site of mtCI and eliminated its neuroprotective effects. Repeated oral administration of C273 (20-80 mg/kg/day) to wild-type mice for one month produced no detectable cardiac or hepatic toxicity, indicating a favorable in vivo safety margin. Importantly, C273 activated these mechanisms and reduced Aβ and p-Tau levels in induced pluripotent stem cell-derived cerebral organoids from patients with sporadic AD. Collectively, these results establish controlled mtCI modulation as a therapeutic strategy and position C273 as a promising disease-modifying candidate for AD.
Red cell antibody and antigen patterns in patients with sickle cell disease: A multi‐center analysis
Covington, Mischa L. , Conrad, Stephanie , Evans, Mariama I., Fasano, Ross M., Forbes, Judith A, Johnson, Carolyn, Karafin, Matthew S. , Nakahara, Hirotomo , Poisson, Jessica , Sikora, James , Sofoluwe, Adeyemi Victor, Sullivan, Jensyn Cone , Thomasson, Reggie R. , Conrad, Stephanie , Karafin, Matthew , Campbell-Lee, Sally , Nakahara, Hirotomo , Poisson, Jessica L , Sikora, James , Cone Sullivan, Jensyn , Thomasson, Reggie R , Lu, Wen , Allen, Elizabeth S. , Chou, Stella T. , Fasano, Ross M. , Juskewitch, Justin E. , Stowell, Sean R. , Lu, Wen

Mayo Clinic

Transfusion | April 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/trf.70213 | PMID 41968490 Get It

Abstract Background Red cell alloimmunization complicates sickle cell disease (SCD) management despite current widespread prophylactic Rh/K matching in the United States (US). Regional antibody patterns remain poorly characterized. Study Design and Methods We conducted a retrospective analysis of 2965 SCD patients from 9 US sites (2010–2022). All hospitals prophylactically match for Rh and K antigens. Each site collected demographics, antigen status, antibody histories, and antibody screen results from their laboratory information system. Results Overall antibody prevalence was 29.7% with dramatic institutional variation (17.9%–56.0%). Alloantibody prevalence was 27.5%. Most autoantibody‐positive patients (74.23%) also had alloantibodies, identifying a high‐risk population. A third of patients with positive antibody histories had negative screens. Pediatric patients showed markedly different antibody profiles than adults. Hospitals’ antibody patterns clustered by patient age rather than geography. Rh and K antibodies were the most common and also most likely to co‐occur, followed by S, Fya, and Jkb antibodies. Antibodies against Jsa (1.82%), V (1.75%), and Kpa (1.69%) were more prevalent than anti‐Jka (1.28%). Despite regional antibody variation, antigen frequencies remained overall consistent. In antigen–antibody pairwise comparisons, 3.15% were antigen‐negative and antibody‐positive reflecting alloimmunization; 0.47% were both antibody‐ and antigen‐positive, suggesting partial/variant antigens. Discussion Substantial institutional variation in antibody prevalence suggests need for site‐specific approaches to testing and prophylactic matching. High co‐occurrence of auto‐ and alloantibodies, antibody immunogenicity patterns, and antigen–antibody discordances support the need for further research and consideration of refined testing and/or matching strategies beyond the current Rh and K standard.